Pharmacovigilance Market Overview
The Pharmacovigilance Market is expanding as pharmaceutical and biotechnology companies face increasing requirements for drug safety monitoring across clinical development and post-marketing stages. Growing biologics and cell and gene therapy pipelines, tighter regulatory obligations, increasing availability of real-world evidence, outsourcing of safety operations, and adoption of artificial intelligence and natural language processing are supporting market growth.
According to the Market Research Future report updated August 25, 2026, the global Pharmacovigilance Market was valued at USD 9.96 Billion in 2025 and is projected to grow from USD 11.13 Billion in 2026 to USD 32.13 Billion by 2035, registering a CAGR of 12.5% during 2026–2035. North America led the market with 46.2% share in 2025, while Asia-Pacific is the fastest-growing region with a projected CAGR of 13.9%. Contract Outsourcing accounted for 51.6% of revenue, Spontaneous Reporting represented 45.5%, and Pharmaceutical Companies held 55.4% of the end-user market in 2025.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/8451
Key players driving innovation and competitiveness in the Pharmacovigilance Market include:
IQVIA
Accenture
Cognizant
ICON plc
Oracle Health Sciences
Parexel
Fortrea
Capgemini
ArisGlobal
Wipro
Tata Consultancy Services
Veeva Systems
ClinChoice
The market is being shaped by expanding biologics and advanced therapy pipelines, tightening post-marketing safety obligations, increasing outsourcing, and rapid adoption of AI-enabled case processing. Contract outsourcing remains the dominant service-provider model as pharmaceutical and biotechnology companies seek flexible cost structures and multi-region regulatory coverage. Spontaneous Reporting continues to represent the largest reporting method, while electronic health record mining is gaining momentum as healthcare data becomes increasingly available for active safety surveillance.
The Pharmacovigilance Market can be segmented by Clinical Trial Phase into Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV. By Service Provider, it includes Contract Outsourcing and In-House. By Type of Reporting, it covers Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining. By End User, it includes Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Hospitals, and Others. By Region, the market includes North America, Europe, South America, Asia-Pacific, and the Middle East & Africa.
The growing need for sophisticated drug-safety monitoring is creating opportunities for pharmaceutical companies, biotechnology firms, contract research organizations, safety-technology providers, hospitals, regulatory-service companies, and healthcare data platforms. AI-powered case processing, automated literature screening, signal-detection platforms, real-world evidence analytics, EHR mining, integrated drug-device safety systems, and decentralized clinical-trial monitoring can support market differentiation and expansion.
Recent Developments and Market Trends:
AI and machine-learning technologies are increasingly being integrated into case processing, literature screening, signal detection, and automated safety narratives.
Cloud-native pharmacovigilance platforms are gaining adoption as sponsors modernize legacy on-premise safety databases and seek scalable multi-region operations.
Electronic health record mining is expanding as real-world data becomes more accessible for active surveillance and adverse-event detection.
Outsourcing is gaining momentum as mid-sized pharmaceutical and biotechnology companies seek flexible safety operations and access to specialized regulatory expertise.
Advanced therapies, including cell and gene therapies, are increasing long-term safety-monitoring requirements and creating demand for specialized pharmacovigilance infrastructure.
Reasons to Buy the Report:
Provides comprehensive insights into the Pharmacovigilance Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across contract outsourcing, in-house safety operations, spontaneous reporting, EHR mining, signal detection, and safety-data management.
Offers detailed segmentation analysis across clinical trial phase, service provider, reporting type, end user, and geographic markets.
Includes competitive intelligence covering leading pharmacovigilance service providers, CROs, technology companies, and safety-platform developers.
Supports informed decisions using market forecasts, regulatory requirements, biologics and advanced therapy pipelines, AI adoption, outsourcing trends, real-world evidence, and regional opportunities.
Future Outlook:
The future of the Pharmacovigilance Market will be shaped by expanding biologics and cell and gene therapy pipelines, tightening regulatory requirements, AI-enabled automation, outsourcing, real-world evidence, and increasing use of electronic health records for active surveillance. Phase IV should remain the largest clinical trial phase with a 34.0% revenue share, while Pre-Clinical is positioned for strong growth at a projected CAGR of 13.6%. Contract Outsourcing should remain the leading service-provider category with a 51.6% share, while In-House operations will continue to be important among large pharmaceutical companies. Spontaneous Reporting should remain the largest reporting method with a 45.5% share, while EHR Mining is positioned for the fastest growth at a projected CAGR of 15.0%. Pharmaceutical Companies should remain the largest end-user segment with a 55.4% share, while Hospitals are positioned for strong growth at a projected CAGR of 15.1%. North America should retain market leadership with 46.2% share, while Asia-Pacific should remain the fastest-growing region at a projected CAGR of 13.9%. Market Research Future projects the market to reach USD 32.13 Billion by 2035 at a CAGR of 12.5%.
➤➤Explore Our Latest Related Reports:
